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ABSTRACT

Chronic or repeated exposure to stressful stimuli can result in several
maladaptive consequences, including increased anxiety-like behaviors and altered
peptide expression in brain structures involved in emotion. Among these structures, the
bed nucleus of the stria terminalis (BNST) has been implicated in emotional behaviors
as well as regulation of hypothalamic-pituitary-adrenal (HPA) axis activity. In rodents,
chronic variate stress (CVS) has been shown to increase BNST pituitary adenylate
cyclase activating polypeptide (PACAP) and its cognate PAC1 receptor transcript, and
BNST PACAP signaling may mediate the maladaptive changes associated with chronic
stress. In order to determine whether chronic stress would potentiate the behavioral
and/or endocrine response to subthreshold BNST PACAP infusion, rats were exposed
to a 7 day CVS paradigm previously shown to upregulate BNST PAC1 receptor
transcripts; control rats were not stressed. Twenty-four hours following the last
stressor, stressed and control rats were bilaterally infused into the BNST with 0.5 µg
PACAP. Startle response to intra-BNST PACAP infusion was assessed post-infusion in
Experiment 1. In Experiments 2 and 3, blood was sampled via a tail nick 30 min
following PACAP infusion to assess the corticosterone response to PACAP following
CVS. We found an increase in startle amplitude and an increase in plasma
corticosterone levels 30 minutes following BNST PACAP infusion only in rats that had
been previously exposed to CVS. These results were likely mediated via PAC1
receptors, as equimolar infusion of the VPAC1/2 receptor ligand vasoactive intestinal
polypeptide (VIP) had no effect on plasma corticosterone levels. These results suggest
that repeated exposure to stressors sensitizes the neural circuits underlying the
behavioral and endocrine responses to BNST PACAP infusion and BNST
PACAP/PAC1 receptor signaling likely plays a critical role in mediating stress
responses.
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CHAPTER 1: LITERATURE REVIEW
1.1. Introduction
Stressors activate several physiological and behavioral systems to promote
homeostasis and survival. However, when stressor exposure becomes severe or
repeated it places enhanced challenges on both physiological and psychological
systems leading to the over activation of the physiological and behavioral systems
typically recruited to reestablish homeostasis. Stressor exposure engages multiple
response systems, including the sympathetic arm of the autonomic nervous systems, the
hypothalamic—pituitary—adrenal (HPA) axis, and central nervous system (CNS)
circuits responsible for fear and anxiety-like behavior. The sustained activation of these
CNS nuclei in response to chronic stressor exposure has been argued to lead to the
maladaptive morphological and functional changes that underlie fear- and anxietyrelated affective states, including altered peptide expression in the brain structures
involved in emotion and increased anxiety-like behaviors (Hammack and May, 2014;
Pego et al, 2008; Schulkin et al, 1998; Vyas et al, 2003). This has led to the idea that
chronic stress encourages and produces stress-related disorders by increasing neuronal
plasticity within stress-responsive nuclei. Indeed, Herman and colleagues suggest that
the connection between limbic structures, affective disorders and HPA axis dysfunction
is likely associated with impaired integration of hippocampal, amygdalar and/or
prefrontal cortical information at one or more of the key subcortical regulatory nodes
such as the bed nucleus of the stria terminalis (BNST) (Herman et al, 2005).
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As mentioned, multiple forebrain limbic regions, including the hippocampus,
medial prefrontal cortex (mPFC) and amygdala, regulate HPA axis in response to
threatening stimuli. The nature of these stressors determines which stress-related
regions are activated and the contribution of these regions to the stress response. For
instance, the central amygdala (CeA) may be selectively tuned to interoceptive or
visceral stimuli (reviewed in Herman et al, 2005). Additionally, processive or
extroceptive stressors or threats with an emotional component requiring limbic
structures activate peripheral stress responses and also stimulate central (behavioral)
stress responding via extrahypothalamic projections to brain nuclei associated with fear
and anxiety. Importantly, these regions consistently show maladaptive changes in
affective disorders. This highlights a critical need for a better understanding of the
pathways by which forebrain limbic structures regulate HPA axis responses as
dysfunction among these structures and circuitry have been highly implicated in the
etiology of several stress-related disorders. For example, posttraumatic stress disorder
(PTSD) and depression both typically manifest HPA axis abnormalities (Choi et al,
2007). For example, the hippocampus contains glucocorticoid receptors and plays a
critical role in the regulation and termination of the HPA axis and has been suggested
to be overactive in stress-related pathologies like hypercortisolemia (reviewed in
Herman et al, 2005). In addition to the hippocampus, the medial prefrontal cortex
(mPFC) is also a critical structure in regulating stress responses. Indeed, the mPFC has
been shown to be critical for inhibiting the PVN; moreover, repeated stressor exposure
has been shown to reduce mPFC neuron activity (Radley, Arias & Sawchenko,
2

2006; Radley and Sawchenko, 2011). The disinhibition of the PVN likely plays a role
in increased stress responding and stress-induced anxiogenic phenotypes. Additionally,
lesions of different mPFC subregions have also been shown to differentially effect HPA
axis output (Radley and Sawchenko, 2011). Finally, the amygdala has also been
implicated in regulating HPA axis activity. Indeed, stimulation of the CeA excites the
HPA axis (Vyas et al, 2003), and repeated stressor exposure increases dendritic
arborization in the basolateral amygdala (BLA) (Herman et al, 2005).
Importantly, almost every limbic region involved in regulating HPA activity
does not project directly to the corticotropin releasing hormone (CRH) synthesizing
PVN. Thus, information from these limbic and forebrain nuclei is relayed to the PVN
via basal forebrain and hypothalamic structures, indicating that the effects on HPA axis
are indirect and depend on the structural and functional integrity of these subcortical
structures/relays. There is considerable opportunity for integration of limbic
information at intermediary sites. Notably, the BNST receives projections from all of
these limbic regions, and in turn, sends projections to the PVN (Dong and Swanson,
2004; 2006). Moreover, there is considerable overlap between the inhibitory (e.g., the
hippocampus and prelimbic cortex) and excitatory (e.g., medial amygdala) inputs
within the BNST, suggesting that limbic information from stress-associated brain
regions may be summated in the BNST, and then sent to the PVN (Herman et al, 2005).
This likely role in integrating and relaying information from stress-associated regions
coupled with the observation’s that BNST coordinates several behavioral response to
stressor exposure (as will be discussed in more detail below), we and others have
3

argued that the BNST represents a critical site of confluence between stress responding
and pathological affective states (Hammack and May, 2014), and the stress-induced
morphological alteration in plasticity within the BNST likely underlie several stressrelated diseases.
1.2. The Bed Nucleus of the Stria Terminalis (BNST)
1.2.1. The BNST and Regulation of the Stress Response
As discussed above, stressors result in the activation of several evolutionarily
important homeostatic systems resulting in the mobilization of these adaptive
responses, including the sympathetic arm of the autonomic nervous systems, the HPA
axis, and the central nervous system CNS circuits responsible for fear and anxiety-like
behavior. The BNST has been argued to modulate all three of the responses to
sustained threats (Hammack and May, 2014; Herman et al, 2005; Radley and
Sawchenko, 2011; Walker and Davis, 2008; Walker et al, 2003, 2009). For instance,
the anterior and posterior BNST sub-regions receive projections from and project to the
PVN to tightly regulate activity and mediate both the endocrine and autonomic
response to stressors (Choi et al, 2007; Dunn, 1987; Radley, Gosselink and Sawchenko,
2009).
The BNST can be divided into cytoarchitecturally and anatomically distinct
subregions. Within the anterior BNST, the dorsolateral region expresses CRH; within
the posterior BNST, the principal nucleus contains GABAergic fibers which also
project to the PVN (Dong and Swanson, 2004; 2006). HPA axis activity can be excited
or inhibited, depending on which of these regions is targeted. Anterior or lateral
4

lesions decreases responses to stress and reduce PVN CRH mRNA; medial lesions have
no effect; and posterior lesions increase resting CRH mRNA expression, suggesting
that distinct nuclei of the BNST differentially regulate HPA axis activity (Choi et al,
2007).
Furthermore, the BNST contains functionally distinct subregions that play
opposing roles in integrating and processing limbic information in response to stress.
For instance, posterior BNST lesions elevated plasma adrenocorticotropic hormone
(ACTH) and corticosterone in response to acute stress, increased stress-induced PVN cfos, and elevated PVN CRH and vasopressin (AVP) mRNA expression; in contrast,
anterior BNST lesions attenuated plasma CORT responses and decreased c-fos mRNA
induction in the PVN but had no effect on CRH and AVP mRNA expression in the
PVN, suggesting that posterior BNST nuclei inhibit HPA axis activity, whereas
anteroventral nuclei excite the HPA axis (Choi et al, 2007).
1.2.2. The BNST and Regulation of Anxiety-like Behaviors
The BNST plays a critical role in the development of anxiogenic behaviors in
response to stressful stimuli and experience, acting as a sort of relay site for the
multiple CNS pathways regulating PVN activity. Consequently, the BNST appears to
play a crucial role in regulating the physiological and behavioral responses to stressor
exposure. Support for this notion comes from studies showing that BNST activity is
heavily implicated in mediating anxiety-like behavioral responding; complimenting
these findings, pharmacological studies have shown anxiogenic agents to increase the
expression of fos and other activation markers in the BNST (Singewald et al,
5

2003). More specifically, activation of the BNST has been argued to mediate anxietylike behavioral responding to diffuse, long-duration and/or unpredictable threats and
may be responsible for mediating anxiety-like emotional states (Walker et al, 2003;
2009; Waddell et al, 2006). Lee and Davis’ (1991) early lesion studies were the first to
suggest that the BNST was critical for anxiety-like behavioral responses; whereas the
CeA was more involved in fear-like responses. Consistent with this view, the BNST
has been implicated in other anxiety-like behaviors including light-enhanced startle
(Walker and Davis, 1997) as well as the stress-induced anxiogenic behaviors resulting
from repeated stressor exposure (Hammack et al, 2004). Additionally, electrical
stimulation of the anterolateral BNST produces many of the endocrine, cardiovascular
and respiratory responses that are elicited by anxiogenic stimuli (Casada and Dafny,
1991). Moreover, anxiogenic pharmacological agents such as yohimbine and mchlorophenylpiperazine (mCPP) increase BNST expression markers of neuronal
activation (i.e., c-fos) and BNST inactivation blocks several anxiogenic behavioral
responses (Singewald et al, 2003).
The data implicating altered BNST structure and function in response to
stressors are not limited to rodent models, as BNST activity has been correlated with
anxiety-like behaviors in nonhuman primates as well as humans (Fox et al, 2008; Kalin
et al, 2005; Somerville et al, 2010; Straube et al, 2007). For example, Kalin and
colleagues (2005) showed that increased BNST activity in rhesus monkeys was
positively correlated with individual differences in freezing behavior in response to eye
contact (i.e., a threatening stimulus) with an intruder. In humans with arachnophobia,
6

BNST activation increases in responses to the anticipation of being shown an artificial
spider (Straube et al, 2007). In aggregate, these findings contend that the BNST
mediates anxiety-like responding when cues predict temporally distant threats (Waddell
et al, 2006) and/or when behavioral responses need to be maintained for long durations
(Walker and Davis, 2008). Thus, BNST-dependent responding drives a behavioral
response distinct from fear and more representative of anxiety in humans, providing
impetus for the idea that maladaptive BNST responding due to stress induced alteration
within this structure, likely underlie some forms of anxiety disorders in humans
(Hammack et al, 2010; 2012).
1.2.3. Effects of Stress on BNST Circuitry
As discussed above, altered BNST functioning is likely crucial for the etiology
of several anxiety disorders associated with repeated stressor exposure (Hammack et al,
2009; 2010; 2012; Pego et al, 2008; Schulkin et al, 1998; Vyas et al, 2003). This
interpretation is supported by findings demonstrating that repeated exposure to stressors
or stress hormones increases anxiety-like behavior which is correlated with enhanced
neuroplasticity within the BNST, including increased neuronal peptide expression
(Hammack et al, 2009; Roman et al, 2014; Stout et al, 2000). For example, Stout and
colleagues (2000) showed that, within the BNST, elevations in CRH and
neuroplasticity are associated with more anxiogenic behavior and anhedonia.
Additional studies have shown that repeated exposure to stressors also enhances
dendritic branching, length, and total BNST volume (Pego et al, 2008; Vyas et al,
2003) and enhances excitatory synaptic transmission (Dumont et al, 2005). Given
7

that stressor exposure is a key component in the development of several affective
disorders and that the BNST is a site of confluence between stress and emotion, these
findings argue that stress-induced alterations in BNST neuronal function and plasticity
likely underlie several forms of chronic anxiety in humans. Thus, chronic exposure to
stressors physically alters BNST neurochemistry, morphology and physiology to
facilitate function and promote increases in fear- and anxiety-like behaviors [reviewed
in Hammack and May, 2014). These findings suggest that BNST neuropeptides with
neurotrophic properties likely act as key mediators of the anxiogenic and maladaptive
effects of chronic stress; however, the mechanisms of BNST signaling/plasticity in
stress-induced anxiety remains to be elucidated.
1.3. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)
The findings discussed above suggest that alterations within the BNST result
from increased neuroplasticity to produce the maladaptive consequences seen following
chronic stress, and implicate neuropeptides with neurotrophic properties as key
mediators of the anxiogenic and maladaptive effects of chronic stress. Several
neurohormones and neuropeptides have been implicated in mediating these effects;
perhaps none more than CRH. Yet, despite its key role in signaling and regulating fearand anxiety-like behaviors, CRH lacks neurotrophic effects. Pituitary adenylate cyclase
activating polypeptide (PACAP) and its cognate G-protein coupled PAC1 receptor have
also been implicated in mediating stress- and anxiety-like responses and unlike CRH,
the PACAP system exhibits neurotrophic properties and enhances neuronal excitability,
and activation of the BNST PACAP system alone has been shown to be
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anxiogenic. Moreover, PACAP and its PAC1 receptor are highly expressed in the
BNST, are selectively upregulated in the BNST following chronic variate stress (CVS),
exhibits neurotrophic properties and enhances neuronal excitability, and activation of
the BNST PACAP system alone has been shown to be anxiogenic. Thus, the BNST
PACAP system emerges as a prime mediator in regulating stress-induced anxiety
(Hammack and May, 2014).
1.3.1. The Role of PACAP in Stress and Anxiety
As mentioned, both PACAP and PAC1 have been implicated in regulating
stress- and anxiety-like responses. Moreover, PACAP and PAC1 are highly expressed
in the BNST and are selectively upregulated following chronic stress. For example,
Hammack, May and colleagues (2009) exposed rats to a 7 day CVS paradigm where
they received one of 5 different stressors each day for the 7 days (Table 1); 24 hours
after the last stressors, 12 stress and fear-related brain regions were micropunched for
quantitative RT-PCR in order to examine whether chronic stress could regulate PACAP
expression in in brain regions implicated in stress-responding and/or anxiety-like
behavior. Among the 12 neural regions examined, results showed that CVS selectively
increased PACAP transcripts more than 10-fold in the dorsolateral BNST; a smaller but
significant 2-fold increase in PACAP transcript was observed in the PVN [reviewed in
Hammack et al, 2010). Among the remaining regions, including the CeA and
basolateral amygdala (BLA), there was no difference in PACAP transcript levels
between CVS and control tissue. CVS also induced an accompanying 2-fold increase in
PAC1 R mRNA in the dlBNST

(Hammack et al, 2009).
9

Table 1

Additionally, the PACAP system exhibits neurotrophic properties and enhances
neuronal excitability. Indeed, within the same tissue set, CVS augmented other stressrelated transcripts in the PVN and amygdala, some of which likely result from PACAP
signaling. For example, following CVS the dlBNST showed a 3-fold and 2-fold
increase in brain-derived neurotrophic factor (BDNF) and TrkB mRNA levels,
respectively (Hammack et al, 2009). PACAP can stimulate neuronal BDNF and/or
TrkB expression and function in several paradigms (Braas et al, 2007). Furthermore,
Zink et al and colleagues have shown CNS BDNF expression to be diminished in
PAC1 receptor knockout animals (Zink et al, 2004). Chronic stress results in long term
structural and functional changes in dlBNST neuronal plasticity and BDNF function
has been associated with anxiety-related behaviors, implicating PACAP-stimulated
BDNF expression as one of the mechanisms underlying stress-induced plasticity within
this structure. In support of this, our lab has that PACAP-treatment of dlBNST explants
in serum-free cultures can increase expression of BDNF transcripts (Hammack and
May, unpublished observation). Further corroboration comes from studies showing that
following chronic stress other CNS nuclei, including the PVN and dorsal raphe nucleus
(DRN), show increases in BDNF

expression (Hammack et al, 2010). The
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changes in BDNF expression within these regions may also reflect stress-mediated
PACAP upregulation and signaling from the BNST as both structures are targets of
BNST projections. These data suggest that among stress-related CNS nuclei, the
dlBNST is a critical target of stress-induced plasticity, and this plasticity may represent
a primary mechanism underlying anxiety disorders in humans.
Further implicating the PACAP/PAC1 receptor system in stress responding,
PACAP and PAC1 receptor null mice show reduced anxiety-like behavior and fear,
including contextual fear conditioning (Girard et al, 2006; Hashimoto et al, 2001; Otto
et al, 2001), diminished HPA axis activation and altered glucocorticoid responses after
prolonged stressor exposure (Hashimoto et al, 2009; Stroth and Eiden, 2010).
1.3.2. Effects of Intra-BNST PACAP on Stress and Anxiety
Additionally, we have shown that intra-BNST PACAP infusion mimics, and
intra-BNST PACAP receptor antagonism prevents, many of the consequences of
chronic stress in the absence of any stressor.
We have shown that bilateral intra-BNST infusions increased acoustic startle
responding, were anxiogenic on the elevated plus maze (EPM), attenuated weight gain,
and increased plasma corticosterone (Hammack et al, 2009; Kocho-Schellenberg et al,
2014; Lezak et al, 2014; Roman et al, 2014). These effects were dose dependent, not
due to ventricular leakage and not sexually dimorphic. Furthermore, these effects were
likely mediated via BNST PAC1 receptors, as the effects were mimicked by intraBNST infusion of maxadilan (selective PAC1 receptor agonist) but not the VPAC1/2
receptor

ligand

vasoactive

intestinal

polypeptide (VIP) (Roman et al, 2014).
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Thus, these results show that BNST PACAP is sufficient to produce a stress and
anxiety-like phenotype in rodents, but they don’t answer the question of whether
endogenous BNST PACAP signaling participates in the behavioral and endocrine
consequences of chronic stress. To address this rats were bilaterally cannulated and
chronically delivered PACAP6-38 (a PAC1/VPAC2 receptor antagonist) during the
week of CVS. Results revealed that PACAP6-38 was able to block the CVS-induced
weight loss and anxiety-like behavior (Roman et al, 2014). Perhaps more importantly,
the results showed that chronic stress sensitized the corticosterone response in reaction
to a subsequent novel stress environment (i.e., open field maze) and acute BNST
PACAP6-38 administration immediately before exposure to the novel environment
attenuated the sensitized portion, specifically, of the corticosterone response to levels
approximating those prior to stressor exposure (Roman et al, 2014). That is, PACAP
antagonism blunted the corticosterone response when the animal had been previously
exposed to chronic stress; but this attenuation was weakened in animals who had only
been exposed to the acute stressor, suggesting that BNST PACAP signaling underlies
the potentiated corticosterone response following chronic stress; but not acute stress.
These results also corroborate Lezak et al. (2014) and further suggest that this system is
recruited in response to long duration stressors and/or multiple stressor exposures
(Stroth and Eiden, 2010). Taken together, the results implicate BNST PACAP signaling
at PAC1 and/or VPAC2 receptors as a necessary system in mediating both the
behavioral and endocrine consequences of chronic stressor exposure (Hammack et al,
2009; Hashimoto et al, 2009; Roman et al, 2014; Stroth and Eiden, 2010).
12

1.3.3. BNST PACAP System in Human Affective Disorders
The PACAP/PAC1 receptor system is highly conserved across species and is
not just important in regulating stress responses in rodents, but has also been implicated
in higher order primates. Indeed, in humans PACAP dysregulation has been associated
with several psychopathologies, including post-traumatic stress disorder (PTSD).
Elevated circulating PACAP levels and a PAC1 receptor gene (ADCYAP1R1) singlenucleotide polymorphism (SNP) predict PTSD symptoms and diagnosis in women;
methylation status was also associated with PTSD independent of gender (Ressler et al,
2011). Importantly for the current study, a PAC1 receptor SNP has also been linked to
startle behavior in male and female children (Jovanovic et al, 2013). These studies
further implicate alterations in BNST PACAP signaling as a critical system mediating
the stress-induced behaviors related to fear and anxiety.
1.4. Aims of the Current Study
The possible upregulation of BNST PAC1 receptors suggests that following
CVS, the BNST may be more sensitive to PACAP release. To address this, the current
experiments examined whether prior chronic stress could potentiate the behavioral
and/or corticosterone response to a subthreshold intra-BNST PACAP infusion. We
observed an increases in startle amplitude and plasma corticosterone levels following
BNST PACAP infusion in stressed rats only. The effects were likely mediated via
PAC1 receptors, as vasoactive intestinal polypeptide (VIP) infusion had no effect on
plasma corticosterone levels. The current results suggest that repeated stressor exposure
sensitizes BNST PACAP signaling, and

this sensitization may play an important
13

role in mediating the maladaptive consequences of stressor exposure, and may be an
important target for the treatment of stress-related disease.
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CHAPTER 2: CVS POTENTIATES THE STARTLE RESPONSE TO INTRABNST PACAP INFUSION
2.1. Introduction
As mentioned above, we have previously examined the roles of BNST PACAP
via direct injection of PACAP38 into the BNST and have shown that this elicits
anxiety-like responses that mimic chronic stress in the absence of any stressor
exposure; moreover intra-BNST PACAP receptor antagonism blocks the stress-induced
consequences (Casada and Dafny, 1991; Roman et al, 2014; Stout et al, 2010; Walker
and Davis, 1997). Specifically, bilateral intra-BNST infusions increased acoustic startle
responding (Walker and Davis, 1997), was anxiogenic on the EPM (Casada and Dafny,
1991) produced anorexia and weight loss (Roman et al, 2014), and increased plasma
corticosterone (Stout et al, 2010). These effects were dose dependent, not due to
ventricular leakage and not sexually dimorphic. Furthermore, these effects were likely
mediated via BNST PAC1 receptors, as the effects were mimicked by intra-BNST
infusion of maxadilan (selective PAC1 receptor agonist) but not the VPAC1/2 receptor
ligand vasoactive intestinal polypeptide (VIP) (Roman et al, 2014). These results show
that BNST PACAP is both necessary and sufficient to produce a stress and anxiety-like
phenotype in rodents. Moreover, we have shown that BNST PACAP and PAC1
receptor transcripts (but not VPAC1/2 transcripts) are upregulated following chronic
stress. These results suggest that the PACAP system may be upregulated and thus more
sensitive to PACAP release following chronic stress. To test this hypothesis, the current
experiment

examined

whether

prior

chronic stress (i.e., CVS) could potentiate
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the behavioral response to a subthreshold intra-BNST PACAP infusion.

2.2. Methods
2.2.1. Animals
Adult male (200-225 g) Sprague-Dawley rats (n=36) were obtained from
Charles River Laboratories (Canada). Rats were single-housed, maintained on a 12h
light/dark cycle (lights on at 0700 h) and food and water were available ad libitum. Rats
were allowed at least one week of habituation in their home cages prior to any
experimentation. All procedures were approved by the Institutional Animal Care and
Use Committee at the University of Vermont.
2.2.2. Surgical Procedures
For intra-BNST infusions, rats were anesthetized with isoflurane vapor (1.5—
3.5%), and secured in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA)
with “blunted” earbars. A midline head incision was made to expose the skull. After
cleaning and sterilizing the skull, four burr holes were made, and four screws were
inserted into the burr holes to provide skullcap stability. Two stainless steel guide
cannulae (26 gauge, PlasticsOne, Roanoke, VA) were lowered at a 20º angle toward the
midline to a point just above the oval BNST, using the following coordinates from
Bregma in mm; AP = -0.1, ML = +3.9, and DV = -5.3 from the surface of the dura
(Lezak et al, 2014). Once the guide cannulae were lowered into place, stylettes were
inserted to ensure cannulae patency and a skullcap was constructed with dental cement
to secure cannulae and stylettes in place. Immediately following surgery, rats were
subcutaneously administered Lactated Ringer’s Solution to provide hydration, and
Carprofen (5 mg/kg) (Pfizer) for analgesia

before being returned to their home cages
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for one week of post-surgery recovery. During recovery all rats were observed and
weighed daily. Additionally, all rats received a second subcutaneous injection of
Carprofen (5 mg/kg) 24h following surgery.
2.2.3. Chronic Variate Stress (CVS)
Following postsurgery recovery, rats were randomly assigned to control or
chronic variate stress (CVS) groups. Control group rats were handled and weighed
daily, and housed in their home cages until infusion. The chronically stressed group of
rats underwent a CVS paradigm in which rats were exposed to one of 5 different
stressors (oscillation, forced swim, footshock, restraint and pedestal) each day for 7
days, as previously described in detail (Hammack et al, 2009). All rats were exposed to
the same order of stressors for the same duration (Error! Reference source not
found.).
For the oscillation stressor, rats were placed inside a plastic chamber 28 cm x 17
cm x 13 cm (L x W x H), that was secured to a clinical rotator and oscillated at low to
medium speed for 30 min.
For forced swim, rats were placed in a cylindrical container 29 cm x 37 cm (D x
H) that was filled with room temperature water to a depth that prevented the rats tail
from touching the bottom. After 5 mins of monitored swimming, rats were placed in a
holding chamber for 30 min prior to being returned to their homecage.
Footshock involved placing the rats inside a Plexiglas conditioning chamber
(Med Associates, St. Albans, VT) 30 cm x 25 cm x 35 cm (L x W x H). After a 5 min
acclimation period, two 1.0 mA 5 s

scrambled footshocks were delivered
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through the grid floor with a 5 minute inter-trial interval. Following the second shock,
rats remained in the chamber an additional 5 min and were then returned to their
homecage.
Restraint consisted of placing each rat into a cylindrical restraining device 9 cm
x 15 cm (D x H) for 60 min. Following the 60 min, rats were returned to their
homecage.
For pedestal, rats were placed on an elevated platform 20 cm x 20 cm (L x W)
that was 60 cm from the floor. Rats remained on the pedestal for 30 min and were then
returned to the homecage.
2.2.4. Startle Apparatus
Each acoustic startle stabilimeter chamber consisted of an 8 cm x 15 cm x 15
cm acrylic and wire-mesh cage with four stainless steel floor bars spaced 18 mm apart.
The cage was suspended between compression springs within an acrylic frame located
within a 90 cm x 70 cm x 70 cm ventilated sound-attenuating cubical. Chamber
movement resulted in the displacement of an accelerometer (Model U321AO2; PCB
Piezotronics, Depew, NY), which was fixed to the bottom of the cage; the resulting
voltage was proportional to the velocity of displacement. The analog output of the
accelerometer was amplified (PCB Piezotronics, Model 483B21) and digitized on a
scale of 0—10 V by an InstruNET analog to digital converter (GW Instruments, Model
100B; Somerville, MA) interfaced to a Macintosh G3 computer. Startle amplitude was
defined as the maximal peak-to-trough voltage during the first 200 ms after the
stimulus onset. Startle responses were

evoked by 50 ms white-noise bursts
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generated by a Macintosh G3 computer sound file, amplified by a Radio Shack
Amplifier (100 W; Model MPA-200; Tandy, Fort Worth, TX), and delivered through a
high frequency speaker (Radio Shack Super-Tweeter; Tandy, Fort Worth, TX) located
5 cm from the back of each cage.
2.2.5. Cannulae Verification
Upon completion of each experiment, rats were anesthetized with sodium
pentobarbital and perfused transcardially with 0.9% saline containing 0.1% heparin
(Sagent, Schaumburg, IL) followed by 10% formalin. Brains were then removed and
postfixed for 24h in 10% formalin. Fixed tissue was sectioned at 60 µm on a cryostat
and mounted on subbed slides for staining with cresyl violet. Following staining, slides
were coverslipped and cannulae placements were verified using a 4x Nikon Objective
on an Olympus light microscope.
2.2.6. Statistics
Statistical analyses were completed using SPSS version 21 (IBM Software,
Armonk, NY) and all graphical representations were completed using GraphPad Prism
version 6 (GraphPad Software, San Diego, CA). Rats were eliminated from analysis for
BNST cannulation experiments if the cannulae fell outside the histological boundary of
the BNST. Additionally, rats were eliminated if their startle amplitude was more than
two standard deviations away from the treatment mean. Two-way ANOVA or Repeated
Measures ANOVA was used to calculate overall group differences and interactions
followed by Tukey’s post hoc comparisons.
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2.2.7. Experimental Procedure
Rats were implanted bilaterally with guide cannulae aimed at the dorsal BNST.
Postoperative care was completed as described above. Following recovery, rats were
administered 2 baseline startle test on consecutive days in which they were placed into
the startle chambers and allowed a 5 min acclimation to the chamber. The response to
33 randomized noise burst (described above) that varied in intensity (95, 100, or
105dB) with a 30 s intertrial interval was then determined as the average response
across the session. After each baseline startle testing session, rats were returned to their
home cages. Based on the average startle across all 3 noise burst intensities for the 2
days of baseline startle rats were “matched” on their average startle to 1 of 4
experimental groups: control/PACAP (n=10), control/vehicle (n=6), CVS/PACAP
(n=10), or CVS/vehicle (n=8), so that baseline startle amplitude did not differ between
groups. For the subsequent 7 days, stressed rats were treated with CVS as described
above; control rats were handled and weighed but not otherwise stressed. On the 8th
day, prior to infusions, all rats were returned to the startle chambers and received a 3rd
startle test that was identical to the prior baseline testing sessions. Immediately after
this third test, rats were removed from the startle chamber and bilaterally infused with
0.5 µl 0.05% bovine serum albumin (BSA)/vehicle (Santa Cruz Biotech., Santa Cruz,
CA) or 0.5 µg PACAP38 (American Peptide Co., Sunnyvale, CA) in 0.5 µl BSA
vehicle. The PACAP dose was chosen as we have previously shown it to be below the
threshold required to produce anxiety-like behavior and corticosterone release when
infused into the BNST (Hammack et al,

2009; Lezak et al, 2014). Infusions were
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completed in the colony room under light restraint. For each infusion: the stylette was
removed and an internal cannula that extended 1 mm beyond the end of the guide
cannula was inserted. Injections were completed using a 10 µl Hamilton syringe
connected to the internal cannula with PE50 plastic tubing. A volume of 0.5 µl was
infused into the BNST over the course of 60 s. Following infusion, the internal cannula
was left in place for an additional 60 s to allow for diffusion of the drug away from the
infusion site. The internal cannula was then removed, and an identical infusion was
completed for the opposite side. After infusions rats were returned to the home cage for
15 minutes until subsequent testing.
Fifteen minutes after infusion, the rats were returned to the startle chamber and
after a 5 min acclimation period, rats were administered a 4th and final startle test that
consisted of 72 startle stimuli that varied in intensity. After the final startle test, rats
were returned to their home cages.
2.3. Results
The BNST of adult male rats was bilaterally cannulated and a subthreshold dose
of PACAP was infused into the BNST of chronically stressed and control rats 15 min
prior to startle testing. BNST injection sites are depicted in Figure 1. Based on histology,
no animals were excluded from analysis; however, outlier analyses revealed 2 subjects
with startle amplitudes more than 2 standard deviations outside the treatment mean, and
thus these subjects were excluded from further analyses.
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Figure 1: Experiment 1 BNST PACAP infusion sites. Placements of cannulae tips for rats that
received 0.5 µg PACAP38 (0.5 µl/side) intra-BNST infusions. Open dots represent site(s) of drug
infusion depicted on coronal sections as a distance (mm) from Bregma (Histological figures modified
from Paxinos and Watson, 2009).

As can be seen in Figure 2, a typically subthreshold dose of PACAP38 bilaterally
infused into the BNST increased startle amplitude later in the startle test session, but only
in rats previously exposed to the CVS paradigm.

Figure 2: CVS Potentiates the Behavioral Response to Intra-BNST PACAP Infusion. Intra-BNST
PACAP infusion increased startle amplitude but only in rats previously exposed to CVS. Data
represent startle amplitude after infusion as a percent of pre-infusion Pretest startle. Significant 3way Blocks x CVS x PACAP interaction, p < 0.01. 22 The effects of PACAP vary across test blocks.

The data are presented as startle amplitude across the 12 3 minute blocks (i.e., 6
30s startle events) of test post-infusion as a percent of the last 9 minutes (18 startle
events) of preinfusion/pretest startle. Repeated Measures Analysis of Variance revealed a
significant 3-way Blocks x CVS x PACAP interaction across all test bins, F (13, 403) =
2.084, p = 0.01. However, there were no statistically significant main effects of CVS or
PACAP, suggesting that the effects of PACAP vary across test blocks depending on
whether the animal was chronically stressed or not.
To further investigate the effects of PACAP across test blocks, the 12 test blocks
were broken into thirds and assessed with two-way ANOVA’s (Figure 3). CVS nor
PACAP had effects on startle amplitude in the first or second thirds of the test session
(Figure 3A and B). In the last third of test (i.e., blocks 9-12), however, intra-BNST
PACAP increased startle amplitude, but only in those rats exposed to CVS (Figure 3C).
Two-way ANOVA revealed a significant CVS x PACAP interaction, F (1, 29) = 5.156, p
= 0.03, but no statistically significant main effects of CVS or PACAP, again suggesting
that stress potentiates the behavioral response to intra-BNST PACAP infusion.

Figure 3: CVS nor PACAP had an effect on startle during the first (A) or second third (B) of the test
session. (C) Intra-BNST PACAP increased startle amplitude only during the last third of the test
session, and only in rats exposed to CVS, suggesting that stress potentiates the behavioral response to
BNST PACAP infusion. Data represents mean +/- SEM. *Significantly different at p < 0.05.
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2.4. Discussion
Results from experiment 1 showed that only those rats that had been previously
exposed to CVS exhibited an increase in startle amplitude at approximately 30 minutes
after a normally subthreshold dose (0.5 µg) of intra-BNST PACAP. These results
suggest that CVS induces plasticity within the BNST, making it more sensitive to
PACAP, resulting in a potentiated behavioral response. Because we have previously
shown these effects to be mediated by PAC1 receptors, and PAC1 receptor transcripts
are increased by CVS, this sensitivity is likely mediated via PAC1 receptor activation;
however, this was not yet confirmed. The current results also further suggest that stressinduced sensitization in behavioral responses to PACAP likely plays a critical role in
mediating the consequences of repeated stressor exposure.
In the current experiment, the potentiated startle effect was not observed until
later in the startle test session at approximately 30 minutes post PACAP infusion.
Walker, Davis and colleagues have shown a similar delayed onset in CRH-enhanced
startle, with effects not becoming evident until 20 minutes after intra-BNST CRH
infusion (Walker et al, 2003). They have argued that fear-potentiated startle represents
conditioned fear; whereas CRH-enhanced startle more closely represents anxiety as it
shows a gradual onset and prolonged effects (Lee and Davis, 1997; Walker et al, 2003).
Thus, the current results suggest that intra-BNST PACAP infusion, like intra-BNST
CRH infusion, also produces a sustained and long-lasting change in behavior and a
persistent anxiety-like state, as opposed to a fear state, and this anxiety-like behavioral
response becomes potentiated following

chronic stress. This interpretation is
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further supported by Hammack et al, who has shown a similar time effect with the
initial PACAP-induced anxiogenic effects increasing over the test sessions as well as a
long-lasting (7 day) intra-BNST PACAP effect on light-enhanced startle, which like
CRH-enhanced startle is argued to be more akin to anxiety (Hammack et al, 2009;
Walker et al, 2003). Thus, although we have shown the greatest effects of intra-BNST
PACAP on the stress (i.e., corticosterone) response at 30 minutes post PACAP
infusion, the current study in aggregate with previous studies suggest that the initial
activation of these PACAP and/or CRH neuroendocrine systems (i.e., long-duration
stimuli) is enough to activate and produce a delayed, yet long-lasting potentiation in
anxiety-like behavior, representing a PACAP induced neuroplasticity within the BNST,
resulting in a long-term increase in anxiety-like behavior.
There is a close relationship between the PACAP and CRH systems; especially
among PVN and BNST neurons where PACAPergic fibers densely innervate CRH
neurons (Kozicz et al, 1997; Missig et al, 2014). Notably, chronic stress has been
shown to increase BNST CRH, mediating an increased anxiety-like behavioral
phenotype (Fox et al, 2008). Furthermore, we have shown increased PACAP
expression within these same brain regions following chronic stress, and intra-BNST
PACAP infusion (current study) as well as intra-BNST CRH enhanced baseline startle.
Together these results suggest that PACAP may mediate increased plasticity and
function specifically within BNST CRH neurons. It could be argued that PAC1
receptors upregulate specifically on BNST CRH neurons. Future studies are needed to
examine this possibility but given the

advancements
25

in

genetics

and viral

vectors, this hypothesis could be examined. For instance, a cre-animal genetically
modified to express GFP in CRH neurons could be double-labeled with a PAC1
receptor antibody; if coexpression increased following chronic stress, this would
suggest that the stress-induced changes in plasticity are mediated via upregulation of
PAC1 receptors on BNST CRH neurons.
The results from Roman et al. (2014) suggest that BNST PACAP/PAC1
receptor signaling mechanisms may coordinate the behavioral and endocrine
consequences of stress. Furthermore, chronic injection of stress levels of corticosterone
fails to produce the chronic stress-induced increases in PACAP transcript (Lezak et al,
2014). These results suggest that the BNST PACAP system likely sits upstream of the
corticosterone system as well as the other physiological outputs of stressor exposure.
The current study further implicates the BNST PACAP system as an upstream mediator
of the corticosterone as intra-BNST PACAP infusion was also able drive an enhanced
startle response. Furthermore, taken with the circuitry laid out by Walker, Davis and
colleagues (Lee and Davis, 1997; Walker and Davis, 1997; Walker et al, 2003), the
results suggest that PAC1 receptors could be upregulated on CRH neurons in the
BNST, leading to stronger activation of these CRH neurons projecting to the nucleus
reticularis pontis caudalis (Lee and Davis, 1997), resulting in the enhanced anxiety-like
startle response. These results also further implicate the BNST PACAP system as a
good potential therapeutic target in stress and anxiety-related pathologies like PTSD.
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CHAPTER 3: CVS POTENTIATES THE ENDOCRINE RESPONSE TO INTRABNST PACAP INFUSION
3.1. Introduction
Experiment 1 determined that intra-BNST infusion of a subthreshold dose of
PACAP38 following CVS does produce an anxious phenotype, as measured by an
increase in startle amplitude. Given that the behavioral response to PACAP was
sensitized following chronic stress, the corticosterone response to PACAP may also be
potentiated. Thus, experiment 2 examined the effects of a subthreshold dose of
PACAP38 following CVS, on the corticosterone response, using procedures similar to
experiment 1.
3.2. Methods
3.2.1. Animals
Adult male (200-225 g) Sprague-Dawley rats (n=39) were obtained from
Charles River Laboratories (Canada). Rats were single-housed, maintained on a 12h
light/dark cycle (lights on at 0700 h) and food and water were available ad libitum. Rats
were allowed at least one week of habituation in their home cages prior to any
experimentation. All procedures were approved by the Institutional Animal Care and
Use Committee at the University of Vermont.
3.2.2. Surgical Procedures
All surgical and post-operative producers were identical to those used in
experiment 1.
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3.2.3. Chronic Variate Stress (CVS)
Following one week of postoperative recovery, rats were randomly assigned by
weight into control (n=21) or CVS (n=18) groups. Control rats were handled and
weighed daily, and housed in their home cages until infusion; stressed rats underwent the
7 days of CVS described above. Twenty-four hours after the last stressor, animals were
weighed and bilaterally infused into the BNST with vehicle or PACAP38 as described
above.
3.2.4. Corticosterone Enzyme-Linked Immunoassay
Following collection of plasma from tail nick blood samples, a corticosterone
enzyme-linked immunoassay (CORT EIA, Enzo Life Sciences, Farmingdale, NY) was
used to determine plasma corticosterone levels. Plasma samples were first diluted 1:30
and heated in a 75ºC water bath for approximately one hour to denature corticosterone
binding globulin (Buck et al, 2011). The interassay coefficient of variation was X.X%
and the sensitivity of the assay was 27.0 pg/ml.
3.2.5. Cannulae Verification
Using procedures identical to experiment 1, rats were anesthetized with sodium
pentobarbital and perfused transcardially with 0.9% saline containing 0.1% heparin
(Sagent, Schaumburg, IL) followed by 10% formalin. Brains were then removed and
postfixed for 24h in 10% formalin. Fixed tissue was sectioned at 60 µm on a cryostat and
mounted on subbed slides for staining with cresyl violet. Following staining, slides were
coverslipped and cannulae placements were verified using a 4x Nikon Objective on an
Olympus light microscope.
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3.2.6. Statistics
Statistical analyses were completed using SPSS version 21 (IBM Software,
Armonk, NY) and all graphical representations were completed using GraphPad Prism
version 6 (GraphPad Software, San Diego, CA). Rats were eliminated from analysis for
BNST cannulation experiments if cannulae placement fell outside the histological
boundary of the BNST. Additionally, rats were eliminated if their mean corticosterone
response was more than two standard deviations away from the treatment mean. Twoway ANOVA was used to calculate overall group differences and interactions followed
by Tukey’s post hoc comparisons. Some comparisons were made using t-test.
3.2.7. Experimental Procedure
Male rats were bilaterally cannulated with guide cannulae aimed at the oval
BNST as described above. Following one week of postoperative recovery, rats were
matched by weight into control (n=21) or CVS (n=18) groups. Control rats were handled
and weighed daily, and housed in their home cages until infusion; stressed rats underwent
the 7 days of CVS described above. Twenty-four hours after the last stressor, animals
were weighed and bilaterally infused into the BNST with vehicle or PACAP38 as
described above. Following bilateral infusion, the rat was returned to the home cage and
remained in the colony room for 30 minutes until blood sampling.
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While blood sampling was conducted in a nearby room the time required to
transport animals and obtain the blood sample was less than 3 min, in order to avoid
contamination of the sample with the increase in corticosterone release associated with
cage removal. Thirty minutes post-infusion, blood was collected via a small tail nick with
the rat under light restraint. This time point was chosen because we have previously
shown increased corticosterone following intra-BNST PACAP (1µg) at 30-60 min post
infusion (Lezak et al, 2014). The sample was immediately placed into a refrigerated
centrifuge and spun between 2000 and 4000 rpm for 15-20 minutes to separate the
plasma. Plasma was then collected and stored at –20 ºC until corticosterone quantification
via a CORT EIA (see above).
3.3. Results
Experiment 2 examined the effects of a subthreshold dose of PACAP38 following
CVS, on the corticosterone response. Using procedures similar to experiment 1, adult
male rats were bilaterally cannulated and infused with a subthreshold dose of PACAP38
following CVS, and plasma corticosterone levels were assessed. BNST injection sites are
depicted in Figure 4. No subjects were removed for cannulae placements, however,
outlier analysis revealed a single rat with unusually high plasma corticosterone (greater
than 2 SD’s above the mean) who was excluded from further analyses.
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Figure 4: Experiment 2 BNST PACAP infusion sites. Cannulae placements for rats that received 0.5
µg PACAP38 (0.5 µl/side) intra-BNST infusions. Open dots represent site(s) of drug infusion depicted
on coronal sections as a distance (mm) from Bregma (Histological figures modified from Paxinos and
Watson, 2009).

There was an increase in plasma corticosterone 30 minutes after intra-BNST
PACAP infusion, but only in the rats previously exposed to CVS (Figure 5). Two-way
ANOVA revealed a significant main effect of CVS, F (1, 37) = 13.05, p < 0.001, and a
significant main effect of PACAP, F (1, 37) = 7.016, p = 0.01, on plasma corticosterone
levels. Additionally, results revealed a trending interaction between CVS and PACAP on
plasma corticosterone levels, F (1, 37) = 3.401, p = 0.07. Further examination of the
trending interaction with subsequent t-test revealed significant differences in plasma
corticosterone levels between the CVS/PACAP and CVS/Vehicle groups, t (17) = 3.53, p
< 0.01 as well as the CVS/PACAP and Control/PACAP groups, t (17) = 3.53, p < 0.01.
There was no significant difference in corticosterone levels between the Control/PACAP
and Control/Vehicle groups, t (20) = 0.54, ns.
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The results of the t-tests further argue the interaction between CVS and PACAP,
suggesting that, like the behavioral response in Experiment 1, CVS also sensitizes the
corticosterone response to intra-BNST PACAP infusion.

Figure 5: CVS potentiates the corticosterone response to intra-BNST PACAP infusion. Plasma
corticosterone was elevated 30 m after BNST PACAP infusion, but only in rats exposed to CVS,
suggesting that stress also potentiates the endocrine response to intra-BNST PACAP infusion. Data
represents mean +/- SEM. *Significantly different at p < 0.05

3.4. Discussion
In experiment 2, rats that had been previously exposed to CVS exhibited an
increase in plasma corticosterone at 30 minutes post PACAP infusion as compared to
non-stressed/control PACAP-infused rats. These results suggest that CVS is capable of
not only potentiating the behavioral response to subthreshold intra-BNST PACAP
infusion, but also the corticosterone response, replicating and extending previous
findings implicating increased plasticity within the BNST, resulting in a sensitizes
response to PACAP signaling. Thus, like experiment 1, experiment 2 further supports a
role for stress-induced plasticity within the BNST, sensitizing this arm of the stress
response to subsequent PACAP release and signaling. This sensitized BNST PACAP
system likely represents one of the primary mediators of the negative consequences of
repeated stressor exposure.
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We know that CRH and PACAP are both are highly expressed in close
proximity, but form distinct populations within the oval nucleus of the BNST (Kozicz
et al, 1997; Missig et al, 2014), and chronic stress increases endogenous PACAP
expression selectively in the oval nucleus in patterns that are distinct from CRH
patterns (Hammack and May, 20014; Roman et al, 2014). Thus, it seems likely that
these distinct populations could interact within the dBNST to drive HPA axis activity
and behavioral responding to stressful or emotional stimuli. Furthermore, the current
study and others suggest that intra-BNST PACAP can mimic and intra-BNST PACAP
receptor antagonism prevents, many of the consequences of chronic stress, including
HPA axis responsiveness and increased levels of corticosterone (Lezak et al, 2014;
Roman et al, 2014). These findings in aggregate suggest a critical BNST to PVN
circuitry that is responsible for driving the enhanced corticosterone response. Thus, it
seems likely that chronic stress produces an increase in endogenous PACAP expression
and levels within the oval nucleus. This likely results in an upregulation of PAC1
receptors within the oval nucleus which could activate local oval nucleus CRH neurons
to drive downstream corticosterone producing neurons in the PVN and a subsequent
increase in corticosterone facilitating the stress response and anxiety-related behavior.
Again, both CRH and PACAP are highly expressed in the dBNST, and the
interaction between these distinct populations are thought to drive PVN activity and
subsequent corticosterone responses. However, it remains unclear as to whether the
dBNST projects directly to the PVN to drive this response. Instead studies suggest that
dBNST plays more of an integration and

regulatory
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function,

while

the

ventrolateral BNST (vlBNST) sends direct projections to the PVN, driving its activity
(Dong and Swanson, 2003; 2006). That is, stress acts on PACAPergic fibers and CRH
neurons in the dBNST, where the information is integrated; this is then sent to the
vlBNST, possibly via known dBNST-vlBNST GABAergic projections or possibly
CRH or PACAPergic projections from dBNST. Within vlBNST, excitatory CRH,
inhibitory GABA and possibly PACAP neurons project to and act on PACAP and/or
CRH neurons within the PVN to produce the corticosterone response. Thus, dBNST
regulates vlBNST, which then projects and drives PVN activity to produce the
corticosterone response.
Despite the significant interaction and differences among the groups in
experiment 2, the control animals still displayed unusually high levels of
corticosterone. Given that this hormone is released in response to a stressor in order to
bring the animal back into homeostasis, and that no other stressors were presented
between the injection and blood collection, it seems like that the current studies
injection procedures were inherently stressful. Indeed, we anticipated this and took
precautions to minimize the natural stress response, however, it appears that the
animals still experienced a stressful experience. This is unlikely to account for the
differences observed among groups however, as experimental animals were exposed to
the same infusion procedures controlling for this possibility.
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CHAPTER 4: INTRA-BNST VIP INFUSION HAS NO EFFECT ON
CIRCULATING CORTICOSTERONE
4.1. Introduction
Experiment 1 determined that intra-BNST infusion of a subthreshold dose of
PACAP38 following CVS results in an anxious phenotype, and experiment 2 to showed
that the endocrine response to PACAP was also potentiated following stress. Experiment
3 was designed to determine whether this sensitized response was mediated via PAC1
receptors. Recall that PACAP binds to PAC1R’s and VPAC1&2 R’s with similar
affinities, whereas VIP binds selectively to VPAC receptors, but not PAC1 receptors.
Thus, experiment 3 was designed to determine whether CVS could potentiate the
response to BNST VIP infusion.
4.2. Methods
4.2.1. Animals
Adult male (200-225 g) Sprague-Dawley rats (n=33) were obtained from Charles
River Laboratories (Canada). Rats were single-housed, maintained on a 12h light/dark
cycle (lights on at 0700 h) and food and water were available ad libitum. Rats were
allowed at least one week of habituation in their home cages prior to any
experimentation. All procedures were approved by the Institutional Animal Care and Use
Committee at the University of Vermont.
4.2.2. Surgical Procedures
All surgical and post-operative producers were identical to those used in
experiment 1 and 2.
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4.2.3. Chronic Variate Stress (CVS)
Following one week of postoperative recovery, rats were randomly matched by
weight into control (n=16) or CVS (n=17) groups. Control rats were handled and
weighed daily, and housed in their home cages until infusion; stressed rats underwent the
7 days of CVS described above.
4.2.4. Corticosterone Enzyme-Linked Immunoassay
Following collection of plasma from tail nick blood samples, a corticosterone
enzyme-linked immunoassay (CORT EIA, Enzo Life Sciences, Farmingdale, NY) was
used to determine plasma corticosterone levels. Plasma samples were first diluted 1:30
and heated in a 75ºC water bath for approximately one hour to denature corticosterone
binding globulin (Buck et al, 2011). The interassay coefficient of variation was X.X%
and the sensitivity of the assay was 27.0 pg/ml.
4.2.5. Cannulae Verification
Using procedures identical to experiment 1 and 2, rats were anesthetized with
sodium pentobarbital and perfused transcardially with 0.9% saline containing 0.1%
heparin (Sagent, Schaumburg, IL) followed by 10% formalin. Brains were then removed
and postfixed for 24h in 10% formalin. Fixed tissue was sectioned at 60 µm on a cryostat
and mounted on subbed slides for staining with cresyl violet. Following staining, slides
were coverslipped and cannulae placements were verified using a 4x Nikon Objective on
an Olympus light microscope.
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4.2.6. Statistics
Statistical analyses were completed using SPSS version 21 (IBM Software,
Armonk, NY) and all graphical representations were completed using GraphPad Prism
version 6 (GraphPad Software, San Diego, CA). Rats were eliminated from analysis for
BNST cannulation experiments if cannulae placement fell outside the histological
boundary of the BNST. Additionally, rats were eliminated if their mean corticosterone
response was more than two standard deviations away from the treatment mean. Twoway ANOVA was used to calculate overall group differences and interactions followed
by Tukey’s post hoc comparisons. Some comparisons were made using t-test.
4.2.7. Experimental Procedure
All procedures were identical to those used in experiment 2. Twenty-four hours
after the last stressor, animals were weighed and bilaterally infused into the BNST with
0.5 µl 0.05% BSA/vehicle (Santa Cruz Biotech., Santa Cruz, CA) or 0.73 µg VIP
(American Peptide Co., Sunnyvale, CA) in 1.0 µl BSA vehicle. The VIP dose was chosen
as it was determined to be equimolar (221µm) to the PACAP dose used in experiments 1
and 2, thereby limiting potential effects due to inherent pharmacodynamic differences in
the ligands used. Following bilateral infusion, the rat was returned to the home cage and
remained in the colony room for 30 minutes until blood sampling.
While blood sampling was conducted in a nearby room the time required to
transport animals and obtain the blood sample was less than 3 min, in order to avoid
contamination of the sample with the increase in corticosterone release associated with
cage removal. Thirty minutes post-infusion,

blood was collected via a small tail nick
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with the rat under light restraint. This time point was chosen because we have previously
shown increased corticosterone following intra-BNST PACAP (1µg) at 30-60 min post
infusion (Lezak et al, 2014). The sample was immediately placed into a refrigerated
centrifuge and spun between 2000 and 4000 rpm for 15-20 minutes to separate the
plasma. Plasma was then collected and stored at –20 ºC until corticosterone quantification
via a CORT EIA (see above).
4.3. Results
Using procedures identical to that of experiment 2, adult male rats were
bilaterally cannulated (Figure 6) and infused with VIP following CVS. No subjects were
removed from the analyses based on cannulae placements or outlier analysis.

Figure 6: Experiment 3 BNST VIP infusion sites. Cannulae placements for rats that received 0.7 µg
VIP (221µM) (0.5 µl/side) intra-BNST infusions. Open dots represent site(s) of drug infusion depicted
on coronal sections as a distance (mm) from Bregma (Histological figures modified from Paxinos and
Watson, 2009).
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Following infusion of VIP into the BNST, plasma corticosterone levels were
assessed. Two-way Analysis of Variance revealed no effect of CVS, F (1, 29) = 0.04, ns,
and no effect of VIP, F (1, 29) = 0.001, ns, on plasma corticosterone levels (Figure 7).
Furthermore, there was no significant interaction between CVS and VIP on
corticosterone levels, F (1, 29) = 2.218, ns, suggesting that the potentiated endocrine
response observed in experiment 2 was mediated via PAC1 receptors, not VPAC
receptors.

Figure 7: Intra-BNST VIP infusion has no effect on the corticosterone response following CVS.
Intra-BNST VIP that was equimolar to the PACAP38 used in experiments 1 and 2 produced no
effect on plasma corticosterone levels following CVS, suggesting that the sensitized corticosterone
response observed in Experiment 2 was mediated via PAC1R’s. Data represents mean +/- SEM.

4.4. Discussion
Results from experiments 1 and 2 provided evidenced for stress-induced
plasticity and alterations in PACAP signaling within the BNST promoting maladaptive
behavioral and endocrine responses. However, the results did not determine which
receptors: PAC or VPAC1/2 were responsible for mediating these responses.
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Recall that PACAP effects can be mediated via 3 receptor subtypes. Of these
receptor subtypes, the PAC1 receptor is selective for PACAP while the VPAC1/2
receptors are demonstrate near equal affinities for PACAP and VIP. Thus, if the effects
are mediated via PAC1 receptors then VIP infusion should have no effect on the
potentiated responses.
Experiment 3 confirmed this hypothesis and showed that equimolar infusion
(0.7 µg) of the VPAC1/2 agonist VIP had no effect on plasma corticosterone levels,
even in stressed rats. Thus, the results seen in experiments 1 and 2 are appear to be
driven via BNST PACAP/PAC1 receptor signaling.
These results are consistent with our previous finding (reviewed in Hammack
and May, 2014) showing that it is PACAP/PAC1, not VPAC, activation and signaling
which is responsible for the stress-induced changes in physiology and behavior.
It should be noted that VIP is found in the oval nucleus of the BNST and could
have some role in the stressed induced plasticity. This doesn’t seem likely, as studies
have shown that PACAP and VIP display differential expression patterns; moreover,
the 2 distinct systems appear non-compensatory in K.O. studies (Girard et al, 2006)
suggesting distinct roles in biological activities.
interpretation.
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Our findings support this

CHAPTER 5: GENERAL DISCUSSION
The upregulation of BNST PAC1 receptors suggests that following CVS, the
BNST may be more sensitive to PACAP release and may be one of the critical
mechanism involved in mediating the maladaptive consequences of repeated stressor
exposure. The current set of experiments were designed to examine whether chronic
stress produces these negative consequences by altering BNST plasticity via a
potentiated PACAP system. Specifically, the experiments examined whether CVS
could potentiate the behavioral and/or corticosterone response to a subthreshold intraBNST PACAP infusion.
Results from experiment 1 showed a significant increases in startle amplitude at
approximately 30 minutes after a normally subthreshold dose (0.5 µg) of intra-BNST
PACAP; however these results were limited to those animals exposed to CVS.
Correspondingly, experiment 2 showed a significant increase in plasma corticosterone
levels at 30 minutes post subthreshold PACAP as compared to non-stressed PACAPinfused rats following BNST PACAP infusion; again, these results were only observed
in those rats subjected to chronic stress. In addition, experiment 3 provided evidence
that these sensitized responses were mediated via PAC1 receptors, as equimolar
infusion (0.7 µg) of the VPAC1/2 agonist VIP had no effect on plasma corticosterone
levels, even in stressed rats. The current results provide evidence for a potentiated
BNST PACAP system and PACAP-signaling following chronic stress. Furthermore,
the results provide a mechanism through which stress, via altered/sensitized
neurotrophic peptide systems and

subsequent modification and plasticity
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within the BNST may promote the maladaptive consequences of stressor exposure.
Additionally, the current study further argues that this system may be an important
target for the treatment of stress-related disease.
Roman et al (2014) showed that PACAP antagonism could only block the
sensitized portion of the corticosterone response to the open field maze (OFM). That is,
PACAP antagonism blunted the corticosterone response only when the animal had been
previously exposed to chronic stress, and thus, presumably had sensitized BNST
PACAP signaling/activity. When the animal had only been exposed to an acute stressor
and ostensibly lacked this sensitized system, PACAP antagonism had no effect on the
corticosterone response, implicating BNST PACAP signaling as a key mediator of the
sensitized endocrine response. The current results corroborate and extend these finding
as a normally subthreshold dose of PACAP following chronic stress was able to
sensitize both the behavioral and corticosterone response to intra-BNST PACAP,
arguing for plastic alterations and/or increased signaling as a critical mechanism in
facilitating the sensitized behavioral and endocrine response following chronic stress;
but not acute stress.
We have argued that PACAP is neurotrophic and enhances plasticity, primarily
within the BNST; moreover, we has suggested that chronic stress promotes stress- and
anxiety-related affective states by modifying the BNST PACAP system (Hammack and
May, 2014). This idea is supported by the current study as chronic stress presumably
altered PACAP signaling (potentially via upregulated PAC1 receptors) within the
BNST, making it more sensitive to

subsequent PACAP release, resulting in a
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potentiated behavioral and endocrine response.
Thus, the results of the current study, in combination with our previous findings
suggest a model (Figure 8) in which the stress-induced plasticity responsible for the
consequences of repeated stressor exposure result from BNST PACAP/PAC1 system
interactions with the CRH system to produce both a potentiated behavioral (i.e.,
anxiety) and physiological (i.e., corticosterone) response. Specifically, chronic stress
appears to upregulate PACAP and PAC1 receptors in the dBNST. The upregulated
PAC1 receptors could be on CRH neurons, or PACAPergic fiber may interact with
CRH neurons in the dBNST. This upregulation and signaling within the dBNST results
in stronger activation of the CRH neurons that project to the nucleus reticularis pontis
caudalis (Lee and Davis, 1997), resulting in the enhanced anxiety-like startle response.
Similarly, the increased activation and signaling within the dBNST PACAP and CRH
neurons could project directly to the PVN to drive the enhanced corticosterone
response, but more likely, enhanced signaling within dBNST CRH and/or GABAergic
(and possibly PACAP) projections to the vlBNST results in stronger activation of CRH
neurons in the PVN and elevated corticosterone release.
PACAP/PAC1 signaling enhances neuronal activation and when combined with
the previous results, suggest this system as a key mediator of the stress induced
plasticity observed in the current study. This could drive subsequent neurochemical
plasticity effects and resulting plasticity in BNST morphology (i.e., increased dendritic
branching and overall BNST volume). For instance, we have shown that PACAP may
be enhancing H-currents, thereby

promoting high frequency firing and more
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peptide release (Lezak and Hammack, unpublished). This could be one mechanism
through which this system promotes multiple levels of plasticity.

Figure 8: Proposed model of the stress-induced plasticity/alterations within the BNST circuits that
mediate the downstream nuclei responsible for the sensitized physiological (corticosterone) and
behavioral (startle) responses following chronic stress.

The results in aggregate support the hypothesis that repeated stressor exposure
physically alters the neurochemistry, morphology and physiology associated with
increases in fear- and anxiety-like behavior to inhibit function within the mPFC and
facilitate function within BNST. Additionally, they emphasize the importance of altered
neuropeptide expression in stress-related pathologies, and further implicate the PACAP
system specifically as a critical system in integrating limbic information within the
BNST to produce stress- and anxiety-related psychopathologies.
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